{"brief_title": "Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma", "brief_summary": "This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.", "condition": "Metastases", "intervention_type": "Drug", "intervention_name": "ABI-007", "criteria": "Inclusion Criteria: - Confirmed Metastatic Melanoma - At least 18 years old - No other active malignancy - Hemoglobin at least 9 - Platelet Count at least 100,000 cells/mm3 - ANC at least 1500 cells/mm3 - AST & ALT less than 2.5X upper limit of normal - Total bilirubin less than 1.5mg/dL - Creatine less than 1.5 mg/dL - Alkaline phosphatase less than 2.5X upper limit of normal - Life expectancy of at least 12 weeks - ECOG performance status of 0-1 - Patient must provide informed consent - Patient must provide authorization to disclose Exclusion Criteria: - Evidence of active brain metastases - The only evidence of metastasis is lytic or blastic bone metastases - Pre-existing peripheral neuropathy of NCI Toxicity Criteria Scale of grade greater than 2 - Received radiotherapy in last 4wks, except if to a non-target lesion only - Clinically significant concurrent illness - Investigator's opinion that patient unlikely to complete study - Cytotoxic chemotherapeutic agent treatment or investigational drug within previous 4wks - History of allergy/hypersensitivity to study drug - Serious Medical Risk Factors determine by the investigator", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00093119.xml"}